跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 8,010 条关于
“C5a pathway”
全部
8,010
临床试验
2,835
药物
314
机构
24
资讯
4,837
8个月前
InflaRx Cuts 30% of Workforce, Deprioritizes COVID-19 Therapy to Focus on Immunology Pipeline
8个月前
InflaRx Reports Encouraging Post-Hoc Analyses for Vilobelimab in Pyoderma Gangrenosum Despite Phase 3 Trial Termination
2个月前
Mirador Therapeutics Licenses KP-301, a Long-Acting Anti-C5a Antibody, Expanding into ANCA-Associated Vasculitis
10个月前
InflaRx to Report Phase 2a Results for Oral C5aR Inhibitor INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria
10个月前
InflaRx's Oral C5aR Inhibitor INF904 Shows Biologic-Like Efficacy in Phase 2a Trials for Hidradenitis Suppurativa and Chronic Spontaneous Urticaria
去年
Complement Activation and Endothelial Injury in Japanese COVID-19 Patients
去年
House Introduces Bill for Conditional FDA Approval Pathway for Rare Disease Drugs
去年
InflaRx's Gohibic (vilobelimab) Receives European Commission Approval for SARS-CoV-2-Induced ARDS
去年
InflaRx's Vilobelimab Receives Positive CHMP Opinion for COVID-19-Induced ARDS
去年
InflaRx Receives EMA Recommendation for Vilobelimab in COVID-19 Treatment
第 1 页,共 484 页
上一页
下一页